Divi’s Laboratories: September ’21 Results Update
Moneylife Digital Team 15 November 2021
Divi’s Laboratories’ (Divi’s) stock is a testament to the fact that the markets are forward-looking in nature. Despite reporting a decent performance in the September quarter, shares of Divi’s plummeted close to 8% on 8 November 2021. Several reasons are attributed to the decline: rising input costs, logistical issues and introduction of Pfizer’s anti-COVID oral drug candidate Paxlovid, which...
Archived Premium Content
This article is outside your subscription period. You can buy this article individually.
SINGLE ARTICLE
Rs 50-Rs 100 + GST
Access will be given ONLY to this article.
 
Already a subscriber ? Log in
Free Helpline
Legal Credit
Feedback